Molecular Devices and MIMETAS Present New Turnkey Solution for Organ-On-A-Chip Market

MolecularDevices logo MIMETAS logo


Sunnyvale, California and Leiden, the Netherlands, February 06, 2017 / B3C newswire / -- In a move to serve customers with ready-to-use solutions for organ-on-a-chip model development and analysis, MIMETAS and Molecular Devices will combine marketing efforts on the OrganoPlate® organ-on-a-chip platform and ImageXpress® Micro Confocal high-content imaging systems. This agreement was announced today at the SLAS2017 conference in Washington.

“OrganoPlates® are designed for ease-of-handling at any throughput, and provide unsurpassed physiological relevance,” said Jos Joore, Managing Director of MIMETAS, “As such, they are perfectly suited for the high-content imaging systems from Molecular Devices. We have been using their equipment in our internal R&D with great success. With ready-to-use protocols and methods for OrganoPlates®, the ImageXpress Micro portfolio is positioned to fully unleash the potential of OrganoPlates®.”

At Molecular Devices, Sarah Vargas-Hurlston, Director of Marketing comments, “We are excited to enter into this marketing collaboration with MIMETAS. Their organ-on-a-chip platform has unique capabilities and a proven fit with our ImageXpress Micro systems. At Molecular Devices, we value MIMETAS’s approach to offer turnkey solutions to customers which aligns with our continual focus to provide better support for customer applications. Together, we offer a solution with unprecedented capabilities in a rapidly developing organ-on-a-chip market.”

MIMETAS (Leiden, The Netherlands) is a biotechnology company developing human organ-on-a-chip tissue models for testing drugs, chemicals and food components in OrganoPlates®. The company develops and validates customized disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection. Mimetas’ unique microfluidic technology and model development know-how enables testing of compounds in high-throughput, showing better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® culture platform supports 3D cell culture under continuous perfusion, with membrane-free co-culture and epithelial and endothelial tubules.

About Molecular Devices, LLC
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables and is dedicated to helping customers unravel the complexity of biological systems. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These innovative instruments, combined with scientific expertise, assays, and analytics tools for protein and cell biology, enable scientists to explore life’s most important questions. The company is headquartered in Silicon Valley, California with offices around the globe.


Jos Joore, Managing Director
This email address is being protected from spambots. You need JavaScript enabled to view it.
+31 85 888 3161

Molecular Devices, LLC
Sarah Vargas-Hurlston, Director of Marketing, Drug Discovery
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 408-203-8692